---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000148"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:16:01.049082+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions cuts 400 jobs, eliminates COO role in restructuring to focus on core MCM and NARCAN

## Summary
- Plan reduces workforce by ~400 employees; charges of $19M-$21M expected in Q3 2023.
- Annualized cost savings targeted >$100M; CDMO services investment de-emphasized.
- COO role eliminated; Adam Havey leaves Sep 30, 2023; Bill Hartzel takes over manufacturing ops.
- Operations reduced at Bayview (Baltimore) and Canton (MA) facilities; maintained for demand response.

## SEC filing metadata
- accession: 0001367644-23-000148
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/0001367644-23-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/ebs-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000148
- JSON: https://secwatch.observer/filing/0001367644-23-000148.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000148.txt

## Key facts
- Executive change
  Bill Hartzel was appointed as Senior Vice President and head of bioservices (new role: manufacturing operations and Executive Management Team) at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Senior Vice President and head of bioservices (new role: manufacturing operations and Executive Management Team)
  source text: The Company also announced that Bill Hartzel, Senior Vice President and head of bioservices, will assume responsibility for manufacturing operations and will join the Executive Management Team, reporting to the interim CEO, Haywood Miller.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/0001367644-23-000148-index.htm
- Executive change
  Adam Havey departed as Chief Operating Officer at Emergent BioSolutions Inc..
  - Action: leaving
  - Role: Chief Operating Officer
  source text: As such, Adam Havey, Executive Vice President and current COO, will be leaving the Company effective September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/0001367644-23-000148-index.htm
- Restructurings & Charges
  Emergent BioSolutions Inc. announced a restructuring with charges of approximately $19.0 million to $21.0 million in charges affecting Bayview facility in Baltimore, Maryland; Canton, Massachusetts; Rockville, Maryland drug product facility (approximately 400 employees).
  - Type: restructuring
  - Charge: approximately $19.0 million to $21.0 million in charges
  - Affected area: Bayview facility in Baltimore, Maryland; Canton, Massachusetts; Rockville, Maryland drug product facility
  - Headcount: approximately 400 employees
  source text: On August 8, 2023, Emergent BioSolutions Inc. (the “Company”) announced an organizational restructuring plan (the “Restructuring Plan”) intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth. The Restructuring Plan includes a reduction of the Company’s current workforce by approximately 400 employees. Decisions regarding the elimination of positions are subject to local law and consultation requirements in certain countries, as well as the Company’s business needs. The Company estimates that it will incur approximately $19.0 million to $21.0 million in charges in connection with the Restructuring Plan, which it expects to incur in the third quarter of fiscal 2023. These charges consist primarily of cash charges related to severance (base bonus), transition services, and estimated benefits cost.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/0001367644-23-000148-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.